Posaconazol

  • Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience.
    Related Articles

    Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience.

    Transpl Infect Dis. 2020 Sep 18;:e13469

    Authors: Vu CA, Rana MM, Jacobs SE, Saunders-Hao P

    Abstract
    BACKGROUND: Invasive fungal disease (IFD) is a serious complication among the immunocompromised population. Isavuconazole is a newer broad spectrum antifungal agent with promising efficacy and safety. However, there remains limited data to favor its use over current first-line agents.
    OBJECTIVES: We aimed to evaluate isavuconazole use and describe rates of associated breakthrough invasive fungal disease (bIFD).
    METHODS: A single-center, retrospective study was conducted to investigate patients receiving isavuconazole for prophylaxis or treatment of IFD between July 1, 2017 and December 31, 2018. Patient-related and outcomes data were extracted from electronic medical records. Descriptive statistics were used to analyze our findings.
    RESULTS: A total of 54 patients were evaluated. Isavuconazole was most commonly prescribed for primary prophylaxis in the acute myeloid leukemia (AML) and allogeneic hematopoietic stem cell transplant (HSCT) population along with treatment for possible invasive fungal disease. The primary reasons for choosing isavuconazole included QTc shortening effects, decreased risk of acute kidney injury, broader spectrum of activity, and concern for breakthrough invasive fungal disease on a different prophylactic agent. We found a breakthrough rate of 8.5% for patients and 7.8% for courses.
    CONCLUSIONS: Isavuconazole appears to be a promising alternative for prophylaxis and treatment of invasive fungal disease. We observed similar bIFD rates and improved tolerability when compared to historical data for posaconazole and voriconazole.

    PMID: 32946658 [PubMed - as supplied by publisher]


    > <>
  • Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations:  II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA).
    Related Articles

    Optimization of anti-microbials in the treatment of Cystic Fibrosis Pulmonary Exacerbations:  II. Therapies for Allergic Bronchopulmonary Aspergillosis (ABPA).

    Pediatr Pulmonol. 2020 Sep 18;:

    Authors: Epps QJ, Epps KL, Zobell JT, Young DC

    Abstract
    This review is the second article in the State-of-the-Art series and aims to evaluate medications used in the treatment of allergic bronchopulmonary aspergillosis (ABPA) in pediatric and adult patients with cystic fibrosis (CF). ABPA is one of several organisms that are found in the airways of CF patients. This review provides an evidence-based summary of pharmacokinetic/pharmacodynamic (PK/PD), tolerability, and efficacy studies of medications including corticosteroids, amphotericin B, azole anti-fungals (isavuconazole, itraconazole, posaconazole, and voriconazole), and a monoclonal antibody omalizumab in the treatment of ABPA and identifies areas where further study is warranted. This article is protected by copyright. All rights reserved.

    PMID: 32946194 [PubMed - as supplied by publisher]


    > <>

Deja un comentario

Este sitio usa Akismet para reducir el spam. Aprende cómo se procesan los datos de tus comentarios.